Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Lille – page 15

1 329 clinical trials in Lille, France across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Lille at a glance
1 329
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

1 329 trials in Lille

Open in trial search

Myelodysplastic syndrome+1

Recruiting

Study of momelotinib in patients with VEXAS syndrome and myelodysplastic syndrome who are dependent on or do not respond to steroid treatment

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Momelotinib Dihydrochloride Monohydrate
  • Sponsor:Groupe Francophone Des Myelodysplasies

Squamous cell carcinoma of head and neck

Recruiting

Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Bicara Therapeutics Inc.

Dermatitis atopic

Recruiting

Study of GHZ339 for treatment of moderate to severe atopic dermatitis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pimecrolimus
  • Sponsor:Novartis Pharma AG

Chronic obstructive pulmonary disease

Recruiting

Study of dupilumab injections to reduce airway inflammation in adults aged 40-85 with chronic obstructive pulmonary disease

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Non-small cell lung cancer

Recruiting

Study of zoldonrasib with daraxonrasib, pembrolizumab and chemotherapy in patients with RAS G12D-mutant non-small cell lung cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Revolution Medicines Inc.

Gastric cancer stage IV+1

Recruiting

Study of ivonescimab with chemotherapy combination for first and second-line treatment in patients with advanced or metastatic gastric and gastroesophageal cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Levofolinate
  • Sponsor:Unicancer

Polymyalgia rheumatica

Recruiting

Study of baricitinib versus placebo for treating polymyalgia rheumatica in adult patients

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Baricitinib
  • Sponsor:Centre Hospitalier Regional Et Universitaire De Brest

Hepatocellular carcinoma

Recruiting

Study of Rilvegostomig with Bevacizumab and Tremelimumab as First-line Treatment for Patients with Advanced Liver Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:AstraZeneca AB

Non-small cell lung cancer

Recruiting

Study comparing RMC-6236 and docetaxel in previously treated patients with advanced or metastatic non-small cell lung cancer who have RAS mutations

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Revolution Medicines Inc.

COVID-19

Recruiting

Study of ibuzatrelvir alone or combined with remdesivir in adults with COVID-19 who have severely compromised immune systems

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:IBUZATRELVIR
  • Sponsor:Pfizer Inc.

Dementia Alzheimer's type

Recruiting

Study of Remternetug for Prevention of Disease Progression in People at Risk for or With Early Onset Inherited Alzheimer's Disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:LY3372993
  • Sponsor:Washington University School Of Medicine

Fallopian tube cancer+1

Recruiting

Study of mirvetuximab soravtansine dosing schedules for patients with platinum-resistant advanced ovarian, peritoneal, or fallopian tube cancer with high folate receptor expression

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Prednisolone Acetate
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Lille

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on head and neck squamous cell carcinoma, exploring novel treatment combinations and targeted therapies. Additional research includes investigations into pancreatic cancer and gastric cancer treatments.

  • Advanced cancer therapies
  • Targeted molecular treatments
  • Combination therapy approaches

Studies are evaluating innovative therapeutic agents and their effectiveness in treating various forms of cancer.

02 Neurological Disorders

Comprehensive research into Alzheimer's disease and Amyotrophic Lateral Sclerosis, examining new treatment approaches and disease mechanisms. Studies also include investigations of essential tremor treatments.

  • Neurodegenerative diseases
  • Movement disorders
  • Brain imaging studies

Research focuses on understanding disease progression and developing targeted interventions.

03 Autoimmune and Inflammatory Conditions

Innovative trials examining treatments for Crohn's disease and Multiple Sclerosis. Research includes novel approaches to managing chronic inflammatory conditions and immune system disorders.

  • Inflammatory bowel diseases
  • Immunotherapy approaches
  • Disease modification strategies

Studies aim to improve treatment outcomes and develop more effective therapeutic options.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.